Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of ES502 Injection in Patients With Advanced Pancreatic Cancer

NCT07649928 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07649928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07649928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of ES502 Injection in Patients With Advanced Pancreatic Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 18, 2026
Completion date
June 30, 2029
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer